Director Declaration

Smith & Nephew Plc
30 June 2023
 

 

Smith & Nephew plc - Director Declaration

 

30 June 2023

 

In accordance with Listing Rule 9.6.14, Smith & Nephew plc (the "Company") announces that Angie Risley, an Independent Non-Executive Director and Chair of the Remuneration Committee of the Company, is to be appointed to the board of InterContinental Hotels Group PLC as a non-executive director effective from 1 September 2023 and as Chair of their Remuneration Committee effective from 1 January 2024.

 

Enquiries

 

Investors / Analysts

Andrew Swift
Smith+Nephew

 

 

+44 (0) 1923 477433

Media

Charles Reynolds
Smith+Nephew

 

 

+44 (0) 1923 477314



 

About Smith+Nephew

 

Smith+Nephew is a portfolio medical technology company that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100